Implementation of an Empiric Transfusion Bundle for Out of Hospital Patients With Haemorrhagic Shock
Launched by MEDICAL UNIVERSITY OF GRAZ · Mar 17, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to look at a special treatment plan for patients experiencing severe bleeding due to trauma, known as hemorrhagic shock. The treatment plan includes giving patients a combination of fibrinogen (a protein that helps blood clot), plasma (the liquid part of blood), and tranexamic acid (a medicine that helps reduce bleeding). The goal is to see if this approach can improve outcomes for patients who are in critical condition.
To participate in this trial, you need to be at least 18 years old and have signs of life-threatening bleeding, which may include rapid heart rate, low blood pressure, or other signs that your body is not getting enough blood. However, if you have had a recent blood clotting issue, are pregnant, or have previously refused to take part in a clinical trial, you may not be eligible. If you join the trial, you will receive the treatment as part of your care, and your health will be closely monitored. This trial is currently not recruiting participants yet, but it aims to improve care for patients who are in critical need.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged, or believed to be aged
- • 18 years or above
- • confirmed or suspected life-threatening bleeding from trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss)
- • need for volume replacement therapy.
- Exclusion Criteria:
- • patient with known recent history of thromboembolic events within the last 6 months
- • known or suspected pregnancy at presentation
- • patient with known refusal of a participation in this clinical trial.
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Gabriel Honnef, MD, PhD
Principal Investigator
Medical University of Graz, Department of Anaesthesiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported